Detalhe da pesquisa
1.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med
; 389(7): 589-601, 2023 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272516
2.
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
N Engl J Med
; 386(16): 1519-1531, 2022 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443108
3.
Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma.
Future Oncol
; 17(16): 2057-2074, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33709779
4.
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(6): 796-807, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32416072
5.
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Invest New Drugs
; 38(2): 433-444, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31028664
6.
A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.
Oncologist
; 24(2): 161-e70, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30352941
7.
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
Am J Hematol
; 98(9): E233-E236, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37354069
8.
Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply.
Lancet Oncol
; 21(8): e371, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32758466
9.
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 33(5): 1100-7, 2015 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26334219
10.
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.
Cancer Chemother Pharmacol
; 93(5): 471-479, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38278871
11.
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Nat Med
; 29(3): 615-622, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36823302
12.
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib.
Neuro Oncol
; 24(5): 770-778, 2022 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34751786
13.
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.
BJU Int
; 108(8 Pt 2): E245-9, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21320274
14.
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Clin Cancer Res
; 27(16): 4491-4499, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34078652
15.
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
JAMA Oncol
; 7(11): 1669-1677, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34554208
16.
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
J Clin Oncol
; 38(15): 1693-1701, 2020 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32208957
17.
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.
J Clin Oncol
; 38(29): 3398-3406, 2020 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32530764
18.
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Nat Med
; 30(1): 302, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37400643
19.
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lancet Gastroenterol Hepatol
; 4(9): 711-720, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31300360
20.
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Clin Cancer Res
; 23(14): 3557-3565, 2017 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28031424